Carcinoma, Non-Small Cell Lung Clinical Trials in Changzhou
3 recruitingChangzhou, China
Showing 1–3 of 3 trials
Recruiting
Phase 2
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC300 enrolled93 locationsNCT06120140
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Carcinoma, Non-Small Cell Lung
Hoffmann-La Roche800 enrolled36 locationsNCT06862869